IMVT
Immunovant IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.90B
P/E Ratio
—
EPS
$-2.77
Beta
0.79
52W High
$36.28
52W Low
$14.32
50-Day MA
$29.17
200-Day MA
$24.34
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-532.49M |
| Operating Margin | 0.00% |
| Return on Equity | -64.80% |
| Return on Assets | -38.40% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.18 |
| Price-to-Book | 7.92 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -14.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $205.31M |
| Float | $78.84M |
| % Insiders | 56.75% |
| % Institutions | 54.73% |
Historical Volatility
HV 10-Day
60.02%
HV 20-Day
120.25%
HV 30-Day
100.99%
HV 60-Day
80.19%
HV Rank
97.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($45.76 target)
2
Strong Buy11
Buy5
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026